iCAD, Inc. (ICAD) Stock Analysis

iCAD, Inc. (ICAD) Healthcare & Pipeline Overview

iCAD, Inc. is a leader in cancer detection and therapy solutions, leveraging AI and image analysis to improve patient outcomes in the healthcare sector, with a robust product portfolio that addresses various cancer types.

What Is the Investment Thesis for ICAD?

iCAD, Inc. presents a unique investment thesis driven by its innovative product offerings and strong market positioning in the cancer detection and therapy space. With a market capitalization of $106M and a gross margin of 86.2%, the company demonstrates robust operational efficiency. The growth catalysts include the increasing adoption of AI in healthcare, projected to reach $45.2 billion by 2026, and the expanding market for breast cancer detection technologies, expected to grow at a CAGR of 14.1% through 2027. However, the company faces risks such as a negative profit margin of -16.4% and the ongoing need for continuous innovation to stay competitive. The combination of these factors positions iCAD for potential growth, contingent upon effective execution of its strategic initiatives.

Based on FMP financials and quantitative analysis

ICAD Key Highlights

Market capitalization of $106M indicates a stable presence in the healthcare sector.

• Gross margin of 86.2% reflects strong operational efficiency and product profitability.
• Negative profit margin of -16.4% highlights the need for improved cost management and revenue growth.
• Beta of 1.40 suggests higher volatility compared to the overall market, indicating potential investment risks.
• No dividend yield, focusing on reinvestment for growth rather than returning capital to shareholders.

Who Are ICAD's Competitors?

ICAD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ICAD's Key Strengths?

Innovative product portfolio with AI-driven solutions for cancer detection.

• High gross margin of 86.2%, indicating strong profitability potential.
• Established market presence with a focus on improving patient outcomes.

What Are ICAD's Weaknesses?

Negative profit margin of -16.4% indicating financial challenges.

• Limited scale with only 66 employees, potentially affecting operational capacity.
• Dependence on a narrow product line may limit market adaptability.

What Could Drive ICAD Stock Higher?

Continued expansion of the AI-driven product portfolio to meet growing market demands.

• Strategic partnerships with healthcare providers to enhance product adoption and market penetration.
• Anticipated regulatory approvals for new products aimed at improving cancer detection.

What Are the Key Risks for ICAD?

Financial-distress signal — its Altman Z-Score of -1.86 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-18.1%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Financial instability indicated by a negative profit margin, requiring effective cost management.
• Dependence on a limited number of products may expose the company to market fluctuations.
• Competitive pressures from larger medical device companies necessitating continuous innovation.

What Are the Growth Opportunities for ICAD?

• Growth opportunity 1: The global AI in healthcare market is expected to reach $45.2 billion by 2026, growing at a CAGR of 44.9%. iCAD's innovative AI-driven products, such as ProFound AI, position the company to capture significant market share by improving diagnostic accuracy and workflow efficiency, thereby enhancing patient outcomes.
• Growth opportunity 2: The breast cancer detection market is projected to grow at a CAGR of 14.1% through 2027, driven by increasing awareness and screening initiatives. iCAD's SecondLook and ProFound AI solutions are strategically aligned to capitalize on this growth, offering advanced detection capabilities that can lead to earlier diagnosis and better treatment outcomes.
• Growth opportunity 3: Expansion into international markets, including Europe and Asia, presents a significant opportunity for iCAD. With increasing healthcare investments and rising cancer incidence rates in these regions, iCAD can leverage its existing products to meet the growing demand for advanced cancer detection and treatment solutions.
• Growth opportunity 4: The increasing prevalence of colorectal cancer highlights the potential for iCAD's VeraLook solution, which aids in the detection of colonic polyps. The colorectal cancer screening market is expected to grow significantly, providing iCAD with an opportunity to expand its product offerings and capture new customer segments.
• Growth opportunity 5: Partnerships with healthcare providers and technology platforms can enhance iCAD's market reach and product integration. Collaborating with key stakeholders in the healthcare ecosystem can facilitate the adoption of iCAD's solutions, driving revenue growth and improving patient care.

What Threats Does ICAD Face?

• Intense competition from established players and new entrants in the medical devices sector.
• Rapid technological changes requiring continuous innovation.
• Regulatory challenges and potential changes in healthcare policies.

What Are ICAD's Competitive Advantages?

• Strong intellectual property portfolio protecting proprietary technologies.
• Established relationships with key healthcare providers and distributors.
• High gross margins indicating operational efficiency and product demand.
• Innovative product offerings that leverage AI for enhanced diagnostic capabilities.

What Does ICAD Do?

Founded in 1984 as Howtek, Inc., iCAD, Inc. transitioned to its current name in June 2002, reflecting its focus on innovative cancer detection and therapy solutions. Headquartered in Nashua, New Hampshire, the company operates in two primary segments: Cancer Detection and Cancer Therapy. iCAD's flagship product, the PowerLook platform, integrates AI algorithms with imaging systems to streamline cancer detection workflows. The SecondLook algorithm uses machine learning to analyze 2D mammography images, identifying suspicious masses and calcifications with high accuracy. Additionally, the ProFound AI tool enhances detection capabilities in digital breast tomosynthesis, while ProFound AI Risk assesses breast cancer risk based on mammography results. The company also offers VeraLook, which aids in detecting colonic polyps via CT Colonography, and the Xoft Axxent electronic brachytherapy systems for treating various cancers. iCAD's products are sold through a mix of direct sales, OEM partners, and distributors, with a market presence extending to Europe, Taiwan, Canada, and China. Over the years, iCAD has evolved into a key player in the healthcare sector, focusing on leveraging technology to improve cancer care and patient outcomes.

What Products and Services Does ICAD Offer?

• Provide advanced image analysis solutions for cancer detection.
• Develop AI-driven algorithms to enhance diagnostic accuracy.
• Offer radiation therapy systems for cancer treatment.
• Sell products through direct sales and partnerships with OEMs.
• Focus on continuous innovation in cancer detection technologies.
• Export products internationally to various markets, including Europe and Asia.

How Does ICAD Make Money?

• Generate revenue through the sale of cancer detection and therapy products.
• Leverage partnerships with healthcare providers and distributors for market penetration.
• Focus on developing proprietary technologies to maintain competitive advantage.
• Invest in research and development to innovate and expand product offerings.

What Industry Does ICAD Operate In?

The healthcare industry, particularly the medical devices sector, is experiencing significant advancements driven by technological innovations such as artificial intelligence and machine learning. The competitive landscape includes established players and emerging startups, all vying for market share in a rapidly evolving field focused on improving cancer care.

Who Are ICAD's Key Customers?

• Healthcare providers including hospitals and cancer care clinics.
• University research institutions conducting cancer studies.
• Veterinary facilities utilizing cancer detection technologies.
• Dermatology offices offering skin cancer treatments.

iCAD, Inc. Financial Trajectory

iCAD, Inc. (ICAD) reported $4.9M in revenue for Mar 2025, a decline of 9.9% compared to the prior quarter. The company recorded a net loss of $833K, with diluted EPS of $-0.03. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ICAD averaged $-0.05 in diluted EPS.

Company Profile

iCAD, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Nashua, US. The company is led by CEO Dana R. Brown. ICAD has traded publicly since 1984.

How iCAD, Inc. Is Valued

iCAD, Inc. carries a market capitalization of $106M, placing it in the micro-cap category.

Return on equity for iCAD, Inc. stands at -18.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.50 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.5%, the inverse of the P/E and a quick read on earnings relative to price.

iCAD, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.86 places it in the distress zone, a signal of elevated financial risk.

iCAD, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 28.0% above estimates on average.

Wall Street analysts project iCAD, Inc. revenue of about $22.3M for fiscal 2026, with EPS near $-0.12.

The most recent 12 insider filings for iCAD, Inc. break down as 12 sales and 0 purchases. On net that is roughly 417K shares disposed (about $1.0M), a signal worth weighing alongside the fundamentals.

ICAD Financials

ICAD Latest News

iCAD, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources